OncoHost developed the first of its kind system that analyzes proteomic changes in blood samples to monitor the dynamics of biological processes induced by the patient (i.e., the host) in response to a given cancer therapy. This proteomic profile is highly predictive of individual patient outcome, thus enabling personalized treatment planning. Our paltfrom also identifies potential drug targets, advancing the development of novel therapeutic strategies.
For patients, Oncologists and payors:
Yale cancer center, Jefferson heatlh system, Rutgers cancer center, Mayo clinic, raybiotech, Israel innovation authrity, BIRD foundation.